MoonLake Immunotherapeutics financials
$11.45−0.95%
Close Sep 29, 2026 · split-adjustedRevenue
Net income
Income statement & cash flow
| Fiscal year | FY25 Dec 31 | FY24 Dec 31 | FY23 Dec 31 | FY22 Dec 31 |
|---|---|---|---|---|
| Revenue | $0.00 | $0.00 | $0.00 | $0.00 |
| Gross profit | $0.00 | $0.00 | $0.00 | $0.00 |
| Gross margin | — | — | — | — |
| Operating income | -$244.8M | -$143.1M | -$54.1M | -$65.1M |
| Net income | -$227.3M | -$118.9M | -$36.0M | -$50.0M |
| Net margin | — | — | — | — |
| Diluted EPS | $-3.53 | $-1.89 | $-0.73 | $-1.70 |
| EBITDA | -$242.2M | -$141.7M | -$53.8M | -$64.9M |
| Operating cash flow | -$196.0M | -$116.6M | -$42.8M | -$55.9M |
| Free cash flow | -$196.0M | -$117.1M | -$43.1M | -$55.9M |
| Diluted shares | 64.5M | 62.9M | 49.1M | 29.4M |
Balance sheet
| Period end | Dec 31 | Dec 31 | Dec 31 | Dec 31 |
|---|---|---|---|---|
| Cash & equivalents | $334.5M | $180.4M | $451.2M | $39.5M |
| Short-term investments | $59.5M | $267.6M | $59.8M | $32.6M |
| Total debt | $74.1M | $0.00 | $0.00 | $0.00 |
| Total assets | $424.4M | $477.9M | $526.5M | $76.8M |
| Total liabilities | $120.0M | $24.5M | $13.0M | $8.1M |
| Shareholders' equity | $304.5M | $453.4M | $513.5M | $68.8M |
From SEC filings via Massive. Fiscal periods follow the company's own calendar; free cash flow is operating cash flow minus capital expenditure.
Sources: Massive / Polygon daily aggregates (split-adjusted) · SEC filings via Massive · FINRA settlements via Massive · Financial Modeling Prep. Figures are dated where shown; research is informational, not investment advice. Methodology